AMGN Chart

1 Month

	Date	Diff
	2025-02-14	-1.96 %
Amgen (AMGN) stock decreased by 1.96% following a significant reduction in holdings by Gladstone Institutional Advisory LLC and broader bearish sentiments from analysts, who downgraded their price targets for the stock.
	2025-02-12	-0.54 %
Amgen (AMGN) stock dropped by 0.54% despite Piper Sandler raising its target price due to generally mixed sentiments from other analysts, including downgrades and varied price targets, along with insider selling activities that may have added to concerns about short-term performance.
	2025-02-10	+0.43 %
Amgen (AMGN) stock increased by 0.43% likely due to positive market sentiment linked to leadership changes at Cadrenal Therapeutics, where the appointment of Dr. James J. Ferguson III as Chief Medical Officer is seen as a strategic move to advance the company's clinical development efforts in specialized cardiovascular therapies. Amgen (AMGN) stock saw a 0.43% increase last night, likely attributed to positive investor sentiment driven by strong institutional ownership and analysts' favorable evaluations compared to other biotech firms, suggesting confidence in the company's long-term growth potential. Amgen (AMGN) stock increased by 0.43% amid contrasting analyses and comparisons with other medical companies, specifically Zai Lab and Quoin Pharmaceuticals, indicating a generally favorable market sentiment towards biotech stocks as well as institutional confidence reflected in Amgen’s collaborations and development pipeline.
	2025-02-07	-1.42 %
Amgen (AMGN) stock fell by 1.42% following a series of mixed analyst ratings, including a price target reduction by Piper Sandler and Citigroup, indicating cautious sentiment among investors despite better-than-expected quarterly earnings. The Amgen (AMGN) stock declined by 1.42% as new research uncovered the symbiotic relationship between myeloid-derived suppressor cells and tumor stem cells in aggressive glioblastomas, highlighting challenges in developing effective immune therapies for such cancers, which may have raised concerns about the company's cancer-related research prospects.
	2025-02-05	+6.5 %
Amgen's (AMGN) stock rose 6.5% after the company reported that the FDA has placed its obesity treatment, AMG 513, on clinical hold, igniting market interest despite the setback in testing. The stock likely went up due to investor optimism or speculation that the overall impact of the hold may be manageable, or because of other positive sentiments surrounding the company's performance or pipeline. Amgen (AMGN) stock rose 6.5% due to the company reporting stronger-than-expected profits for the latest quarter, driven by growth from its Repatha medication. Amgen's stock increase was primarily attributed to better-than-anticipated quarterly results and the success of their Repatha medication, which contributed to its financial growth.
	2025-02-03	+1.21 %
Amgen (AMGN) stock rose by 1.21% ahead of its upcoming quarterly earnings announcement, driven by investor optimism regarding expected earnings of $5.04 per share and a newly declared increased dividend of $2.38 per share.
	2025-01-31	+0.49 %
Amgen (AMGN) stock rose by 0.49% despite Citigroup reducing its price target from $310 to $295, but the increase may be attributed to positive quarterly earnings results that exceeded analysts' expectations and an upcoming dividend increase. Amgen (AMGN) stock was up 0.49% as analysts maintain a consensus "Hold" rating with various price target adjustments and institutional investors increasing their stakes, signaling confidence in the company's performance after a strong earnings report that exceeded expectations with a 23.2% revenue increase year-over-year.
	2025-01-27	+2.73 %
Amgen (AMGN) stock rose by 2.73% due to a mix of hedge fund activities, positive quarterly earnings that exceeded expectations, and an increase in its dividend payout. Amgen (AMGN) stock increased by 2.73% following the Royal Bank of Canada's reissuance of an outperform rating and a price target of $324.00, amidst positive quarterly earnings results and favorable analyst sentiment.
	2025-01-24	-0.89 %
Amgen (AMGN) stock decreased by 0.89% following a report from William Blair that lowered its Q4 2024 earnings per share estimates from $5.12 to $5.05, contributing to negative investor sentiment. Amgen (AMGN) stock fell by 0.89% following a series of downgraded price targets from multiple analysts, including Truist Financial and Bank of America, suggesting caution among investors despite the company's strong recent earnings report.
	2025-01-21	+0.99 %
Amgen (AMGN) stock rose by 0.99% following positive quarterly earnings that exceeded analysts' expectations, signaling strong financial performance and potentially bolstering investor confidence, despite some hedge funds reducing their stakes. Amgen's (AMGN) stock rose by 0.99% amid ongoing developments in the competitive landscape of weight-loss drugs, particularly following the company’s promising results with its experimental medication MariTide, which showed an average weight loss of 20% in a clinical trial. The increase in Amgen's stock can be attributed to investors’ renewed optimism regarding its weight-loss drug, MariTide, following disappointing results from competitors, which leaves Amgen well-positioned in the market for anti-obesity treatments.
	2025-01-16	+0.18 %
Amgen (AMGN) stock rose by 0.18% likely due to increased institutional investment, with Moody National Bank Trust Division raising its stake and other investors also boosting their holdings, signaling strong confidence in the company's performance and prospects.
	2025-01-15	+0.69 %
Amgen's (AMGN) stock rose by 0.69% due to increased institutional investment, with Brookstone Capital Management boosting its stake by 8.2%, reflecting positive market sentiment following strong quarterly earnings and a recent dividend increase.
	2025-01-14	-1.14 %
Amgen (AMGN) stock declined by 1.14% due to market dynamics that may include competition and investor sentiment towards other pharmaceutical stocks, as highlighted in the comparative analysis between Arrowhead Pharmaceuticals and Janone, which showed Arrowhead's superior performance metrics that could be drawing investors' attention away from Amgen. Amgen (AMGN) stock fell by 1.14% due to mixed analyst sentiments and potential market reactions to its recent financial performance and changes in institutional investor positions. Amgen (AMGN) stock was down 1.14% due to a broader tech sell-off in the market, where investors took profits in high-performing sectors and rotated towards non-tech shares amidst rising interest rates affecting growth-oriented stocks. Amgen (AMGN) stock declined by 1.14% amid a broader tech sell-off affecting the Nasdaq Composite, as investors rotated out of tech shares in favor of more stable sectors, responding to rising interest rates and profit-taking from previously high-performing stocks.
	2025-01-13	+3.04 %
Amgen (AMGN) stock rose by 3.04% due to a generally positive market trend where a majority of S&P 500 sectors saw gains, and specific bullish sentiments in biotech were heightened by upcoming industry events like the J.P. Morgan Healthcare Conference.
	2025-01-10	-0.75 %
Amgen (AMGN) stock decreased by 0.75% following a reduction in its target price by Truist Financial from $333.00 to $298.00, which contributed to a cautious sentiment among investors leading to the decline. Amgen Inc. (AMGN) stock declined by 0.75% after First Hawaiian Bank slightly reduced its holdings in the company, amidst additional changes in ownership by other institutional investors and varied analysts' ratings on the stock.
	2025-01-07	+1.34 %
Amgen (AMGN) stock rose by 1.34% due to increased investment from institutional investors and favorable analyst ratings following the company's strong quarterly earnings report that exceeded expectations.
	2025-01-06	-1.01 %
Amgen (AMGN) stock fell by 1.01% following a period of increased institutional investment, with mixed analyst ratings suggesting caution about its future price targets and a declining market response to the company's recent performance. The decline in Amgen's stock may be attributed to the recent reduction in price targets by several brokerages, indicating a possibly negative outlook, as well as the stock's significant reliance on institutional holdings alongside market volatility factors. Amgen (NASDAQ:AMGN) stock fell by 1.01% due to a mix of lower institutional investment and changes in price targets by several brokerages, indicating some market hesitance. Amgen (AMGN) stock declined by 1.01% amid significant stake increases by various institutional investors and mixed analyst ratings, potentially reflecting market volatility or profit-taking behaviors among traders. Amgen (AMGN) stock fell by 1.01% due to general market trends and fluctuations influenced by institutional investors adjusting their holdings, as well as potentially cautious sentiment following recent changes in analyst ratings and guidance on stock performance. Amgen (AMGN) stock fell by 1.01% despite strong quarterly earnings, likely due to a combination of profit-taking by investors following recent performance, a higher-than-expected dividend payout ratio, and the general sentiment around the stock's valuation in light of analyst ratings.
	2025-01-03	+0.75 %
Amgen (AMGN) stock rose by 0.75% despite a reduction in its price target by Piper Sandler due to positive quarterly earnings results that exceeded analysts' expectations, alongside an increase in its quarterly dividend. Amgen (AMGN) stock rose by 0.75% likely due to a combination of recent institutional investment activity, positive earnings results exceeding analyst expectations, and an increase in its quarterly dividend payout from $2.25 to $2.38, which may have boosted investor confidence.
	2025-01-02	-0.52 %
Amgen (AMGN) stock fell by 0.52%, attributed to mixed ratings and target adjustments from several equity research analysts, with some raising concerns while others maintained a more neutral stance on the company. Amgen (AMGN) stock fell by 0.52% last night, reflecting a broader trend as it was one of the worst-performing Dow Jones stocks in 2024, declining by 9.5% amidst a strong market rally for other stocks. The decline in Amgen's stock price may be attributed to its overall performance in 2024, where it was among the bottom three performers in the index.
	2024-12-26	-0.5 %
Amgen (AMGN) stock fell 0.5% due to concerns over the continued impact of drug price negotiations mandated by the Inflation Reduction Act, which may limit the company's profit potential from its products, particularly Enbrel, while addressing ongoing issues related to the pharmaceutical industry's patent practices and the government's negotiating power.
	2024-12-17	-0.21 %
Amgen (AMGN) stock declined by 0.21% amid a broader downturn in the Dow Jones Industrial Average, primarily driven by a significant drop in UnitedHealth Group's shares following the tragic killing of its CEO, which has negatively affected investor sentiment toward the health care sector as a whole. Amgen (AMGN) stock decreased by 0.21%, potentially due to broader market fluctuations and competition from emerging companies like Nektar Therapeutics and Aravive, which could be affecting investor sentiment in the biotechnology sector. Amgen (AMGN) stock fell by 0.21% amid a broader decline in the Dow Jones Industrial Average, which is experiencing its longest losing streak in nearly 50 years, driven by a sell-off in healthcare stocks, including Amgen, and the Dow's lack of participation in the tech rally that has benefitted other major indexes.
	2024-12-13	-1.26 %
Amgen (AMGN) stock recently declined by 1.26%, largely influenced by market dynamics affecting small-cap medical companies like ProKidney and Vigil Neuroscience, which are compared in terms of investment potential, institutional ownership, and analyst recommendations.
	2024-12-12	+0.24 %
Amgen (AMGN) stock rose by 0.24% following an upgrade from "buy" to "strong-buy" by StockNews.com, along with positive movements in various analysts' ratings and a strong quarterly earnings report. Amgen (AMGN) stock increased by 0.24% despite receiving an "underperform" rating from Bank of America, indicating mixed investor sentiment driven by strong earnings and revenue growth, as well as varying ratings and price targets from several research firms.
	2024-12-10	-0.68 %
The article discusses a comparison between two medical companies, BeiGene and Evoke Pharma, highlighting that BeiGene is viewed more favorably by analysts due to a stronger consensus rating and potential upside, while mentioning that Amgen's stock (AMGN) fell by 0.68% without providing specific reasons for the decrease. Amgen's stock may have gone down due to a variety of market factors, but the article does not specify any particular reasons related to Amgen itself.
	2024-12-09	+1.85 %
Amgen (AMGN) stock rose by 1.85% following its strong quarterly earnings report, which beat analyst expectations and demonstrated significant revenue growth compared to the previous year.
	2024-12-05	-1.41 %
Amgen (AMGN) stock declined by 1.41% due to changing investor sentiment in response to interest rate shifts, typically favoring stable, high-yielding equities amidst expectations of monetary easing.
	2024-12-04	-0.02 %
Amgen (AMGN) stock experienced a slight decline of -0.02% following Eli Lilly's positive Phase III trial results for its weight loss therapy Zepbound, which demonstrated significantly greater weight loss compared to Novo Nordisk's Wegovy, intensifying competition in the obesity drug market. The decline in Amgen's stock is likely due to increased competitive pressure in the obesity treatment market, particularly from Lilly's successful trial results which could divert interest and investment away from Amgen's obesity therapies.
	2024-12-03	+0.08 %
Amgen (AMGN) stock gained 0.08% recently despite lowered FY2024 earnings estimates from analysts, as it continues to benefit from a solid quarterly earnings report, robust revenue growth, and strong dividend payouts. The rise in Amgen's stock can be attributed to its recent positive earnings results, which surpassed analysts' expectations, along with the confidence expressed by some analysts maintaining or upgrading their recommendations for the stock.
	2024-12-02	-1.69 %
Amgen (AMGN) stock fell by 1.69% following a significant reduction in its position by Bridgewater Associates LP, which cut its holdings in the company by 61.4%, alongside downward adjustments to price targets by several equities analysts.
	2024-11-26	-4.76 %
Amgen (AMGN) stock dropped 4.76% due to disappointing results from a mid-stage trial of its weight loss drug, MariTide, which showed lower-than-expected patient weight loss outcomes compared to Wall Street projections. Amgen (AMGN) stock fell 4.76% after the company reported mid-stage trial results for its weight loss drug MariTide, which, despite showing a 20% average weight loss over 52 weeks, failed to meet Wall Street's expectations of a higher efficacy compared to competing medications. The stock decline is attributed to the trial results being at the lower end of market expectations when investors were hoping for a greater weight loss percentage from the treatment. Amgen (AMGN) stock fell by nearly 8% due to disappointing trial results for its experimental weight-loss drug MariTide, which did not meet investor expectations for effectiveness. Amgen Inc (AMGN) stock dropped 4.76% following the release of disappointing Phase 2 study data for its obesity treatment MariTide, which showed only up to 20% average weight loss in obese patients. Amgen (AMGN) stock fell by 4.76% following the announcement of positive but preliminary results from a clinical trial of its experimental obesity drug, MariTide, which has yet to undergo further trials and receive FDA approval, leading to uncertainty about its future market performance. Amgen (AMGN) stock declined by 4.76% following the announcement of positive Phase 2 clinical trial results for its investigational obesity treatment MariTide, possibly due to investors' concerns about market competition and the need for further validation in Phase 3 trials despite the promising data.
	2024-11-25	-0.18 %
Amgen (AMGN) stock declined by 0.18% after Zacks Research reduced its Q4 2024 earnings estimates from $5.40 to $4.86 per share, indicating concern over the company's financial performance.
	2024-11-21	+0.71 %
Amgen (AMGN) stock was up 0.71% last night, likely due to positive investor sentiment and strong institutional ownership, indicating confidence in the company's long-term performance compared to other medical companies like Arrowhead Pharmaceuticals and PaxMedica.
	2024-11-20	+2.83 %
Amgen (AMGN) stock rose by 2.83% despite a broader selloff in pharmaceutical companies producing weight loss drugs after Robert F. Kennedy Jr. was nominated to lead the Department of Health and Human Services, as analysts believe the market's fears regarding potential policy changes impacting these drug companies are overblown and that their fundamentals remain strong.
	2024-11-19	+0.43 %
The article discusses recent findings from Silence Therapeutics' clinical study on zerlasiran, revealing concerns about its competitive position against Amgen's olpasiran in lowering Lp(a) levels, leading to a slight increase in AMGN stock by 0.43%. Amgen's stock likely rose due to analysts’ growing skepticism about the competitive effectiveness of another company's treatment compared to Amgen’s product, enhancing the perceived strength of AMGN's position in the market.
	2024-11-18	-1.71 %
Amgen (AMGN) stock fell by 1.71% following new coverage that rated the stock as "peer perform" and after Wells Fargo downgraded its rating from "overweight" to "equal weight."
	2024-11-15	-4.16 %
Amgen (AMGN) stock fell 4.16% amid rising concerns in the healthcare sector following President-elect Donald Trump's decision to appoint Robert F. Kennedy Jr., a known vaccine skeptic, to lead the Department of Health and Human Services, leading to fears over the regulation of pharmaceutical products.
	2024-11-13	+0.87 %
Amgen (AMGN) stock rose by 0.87% despite concerns raised by Cantor Fitzgerald about potential safety risks related to the company's obesity candidate, MariTide (AMG-133), indicating resilience or positive market sentiment among investors. Amgen's stock rose by 0.87% after the company clarified there were no bone safety concerns regarding its experimental obesity drug, addressing investor worries following a prior drop in its share price due to negative early-stage study data.
	2024-11-12	-7.14 %
Amgen (AMGN) stock dropped over 7% due to concerns raised by analysts regarding potential bone density loss linked to earlier-stage trial data for its weight loss drug, MariTide; while some analysts view this as a potential risk, others believe the market's reaction was an overreaction pending further data from larger patient trials.
	2024-11-11	-1.07 %
The article discusses a study on the relationship between blood protein profiles and the risk of relapse in Crohn's disease patients who discontinue infliximab, but it does not provide information on the reasons behind the recent -1.07% decline in Amgen (AMGN) stock. The decline in Amgen (AMGN) stock may be attributed to various market factors such as investor sentiment, broader market trends, or company-specific news that is not detailed in the article provided.
	2024-11-08	+1.05 %
Amgen (AMGN) stock rose by 1.05% amid significant changes in the Dow Jones Industrial Average, which has recently seen major fluctuations and stock replacements. The increase in Amgen's stock could be attributed to its inclusion in the Dow Jones Industrial Average, reflecting investor confidence amid the index's ongoing reshuffling.
	2024-11-06	+0.78 %
Amgen (AMGN) stock rose by 0.78% following an upgrade in FY2024 earnings estimates by Leerink Partners, which now anticipates earnings of $19.53 per share, exceeding previous estimates and boosting investor confidence.
	2024-11-05	+0.75 %
Amgen (AMGN) stock rose 0.75% after Cantor Fitzgerald raised its FY2024 earnings per share estimate from $19.48 to $19.61 and reported better-than-expected quarterly earnings and revenue, indicating strong financial performance.
	2024-11-04	-0.72 %
Amgen (AMGN) stock decreased by 0.72% likely due to broader market dynamics and the influence of major companies like Nvidia joining the Dow Jones Industrial Average, which can shift investor focus and sentiment away from older pharmaceutical stocks. Amgen (AMGN) stock was down by 0.72% amid competition in the weight-loss drug market following Viking Therapeutics' positive clinical trial results for its experimental weight-loss drugs, which heightened market volatility and investor sentiment towards competing pharmaceutical companies.
	2024-10-30	-0.15 %
Amgen (AMGN) stock saw a decline of 0.15% amid overall market weakness influenced by poor earnings results and ongoing foreign fund outflows that negatively impacted market sentiment. Amgen (AMGN) stock fell by 0.15% following a new investment by Highline Wealth Partners LLC, which acquired 4,045 shares in the company during the 3rd quarter, suggesting cautious investor sentiment amidst market fluctuations. Amgen (AMGN) stock experienced a slight decline of 0.15%, attributed to mixed ratings from analysts, including a downgrade from Truist Financial, which lowered the stock from a "buy" to a "hold" status. Amgen (AMGN) stock dropped by 0.15% amid a broader decline in the Indian stock market driven by weak global trends, disappointing earnings reports, and ongoing foreign fund outflows affecting overall market sentiment.
	2024-10-29	-0.37 %
Amgen (AMGN) stock fell by 0.37% ahead of its upcoming earnings report, as investors may be concerned about the company's previous earnings miss, which could affect confidence in future performance despite strong revenue growth. Amgen (AMGN) stock fell by 0.37%, despite Strategic Wealth Investment Group LLC increasing its holdings by 10.3% in the third quarter, suggesting that broader market factors or investor sentiment may be influencing the stock's decline. Amgen's (AMGN) stock fell by 0.37% following analysts at Zacks Research lowering their Q1 2025 earnings estimates from $4.79 to $4.69 per share, indicating concerns about the company's future profitability.
	2024-10-28	+0.06 %
Amgen (AMGN) stock experienced a 0.06% increase, attributed to First American Bank boosting its holdings in the company by 24.1% in the third quarter. Amgen (AMGN) stock rose by 0.06% amidst a busy week for Wall Street, highlighted by earnings reports from major companies and economic data releases, contributing to a generally positive sentiment in the healthcare sector. The rise in Amgen's stock can be attributed to expectations for strong earnings and growth forecasts within the healthcare sector, particularly given the context of upcoming earnings reports and economic indicators that may positively influence investor sentiment. The article discusses the comparison between TScan Therapeutics and ProKidney, highlighting ProKidney's more favorable analysts' outlook despite its lower revenue, but it does not provide specific reasons for Amgen's (AMGN) slight increase of 0.06% in stock price last night. The increase in Amgen's stock could be attributed to positive performance in the biotech sector or investor sentiment towards its ongoing collaborations and developments. Amgen (AMGN) stock increased by 0.06% as institutional investors, such as Arkadios Wealth Advisors and others, have recently raised their stakes in the company, indicating positive sentiment among major shareholders.
	2024-10-25	+0.41 %
Amgen Inc. (AMGN) stock increased by 0.41% as Nicholson Wealth Management Group LLC purchased a new stake in the company, indicating growing investor confidence and interest in the stock. Amgen (AMGN) stock rose 0.41% likely due to the promising findings from a Johns Hopkins study indicating that newly identified lymph node-like structures in liver tumors after immunotherapy might enhance treatment responses in patients with hepatocellular carcinoma, reflecting progress in cancer treatment that could positively impact investor sentiment toward the company.
	2024-10-24	+0.25 %
Amgen (AMGN) stock rose by 0.25% following a disclosure that Private Advisor Group LLC reduced its stake in the company by 3.5% in the third quarter, possibly indicating investor confidence in the stock despite the sell-off. The article discusses Amgen Inc. (AMGN) stock, which rose by 0.25%, mentioning changes in institutional investments and analysts' ratings indicating a consensus "Moderate Buy" with various price targets set between $320.00 and $380.00. The increase in AMGN stock can be attributed to positive analyst ratings, institutional investors increasing their stake in the company, and solid revenue growth reported recently.
	2024-10-23	-1.49 %
Amgen (AMGN) stock fell by 1.49% despite a consensus recommendation of "Moderate Buy" from twenty-four brokerages, primarily due to mixed ratings with multiple analysts assigning hold and sell ratings. Amgen (AMGN) stock is down 1.49% likely due to mixed analyst ratings and a recent earnings miss, which may have led to decreased investor confidence. Amgen (AMGN) stock fell by 1.49% likely due to a downgrade in rating from Truist Financial and mixed analyst opinions, despite recent investments from large institutional buyers. Amgen (AMGN) stock declined by 1.49% after a recent earnings report revealed that its earnings per share fell short of analyst estimates, signaling potential concerns about its financial performance.
	2024-10-22	+0.92 %
Amgen (NASDAQ: AMGN) stock increased by 0.92% following increased institutional investments, including significant stake increases from firms like Cyndeo Wealth Partners LLC and Capital International Investors, which generally boosts market confidence in the company's future performance. The article discusses a comparison between Entera Bio and Artiva Biotherapeutics, focusing on their financial performance and growth potential, and mentions that Amgen (AMGN) stock rose by 0.92%, likely due to positive market sentiment and strong institutional support that suggests confidence in the company’s long-term growth prospects. Amgen (AMGN) stock rose 0.92% following a report that Raleigh Capital Management reduced its holdings in the company by 36.9%, indicating potential market confidence in Amgen's performance despite the decrease in their shares. Amgen (AMGN) stock rose by 0.92% following Cantor Fitzgerald's reissue of an "overweight" rating and a target price of $405.00, indicating positive investor sentiment and confidence in the company's potential for growth. Amgen (AMGN) stock rose 0.92% following a price target increase from TD Cowen, which raised it from $381.00 to $383.00 and maintained a buy rating, indicating positive analyst sentiment about the company's performance and prospects.
	2024-10-21	-1.53 %
Amgen (AMGN) stock fell by 1.53%, despite a significant increase in holdings by Penn Davis Mcfarland Inc., due to broader market trends or potential investor concerns impacting the biopharmaceutical sector. Amgen (AMGN) stock fell by 1.53% despite TD Cowen raising its target price on the shares from $381 to $383 and maintaining a "buy" rating, indicating market volatility or investor reactions may have influenced the decline regardless of the positive outlook.
	2024-10-18	+0.1 %
Amgen (AMGN) stock rose 0.1% last night, continuing a 13% increase this year, amid strong earnings reports and anticipation of clinical-trial data for its drug. The stock's slight uptick can be attributed to investor optimism surrounding its performance and upcoming trial results. Amgen (AMGN) stock saw a slight increase of 0.1% following a significant 4,946.4% increase in ownership by Teamwork Financial Advisors LLC, which boosted its stake in the company substantially in the third quarter.
	2024-10-16	-1.06 %
Amgen (AMGN) stock fell by 1.06% partially due to Foster Victor Wealth Advisors LLC reducing its position in the company by 32.9% during the 3rd quarter.
	2024-10-15	+0.14 %
Amgen (AMGN) stock was up 0.14%, possibly due to overall positive market movements or investor sentiment, despite Wesbanco Bank Inc. reducing its stake in the company. Amgen (AMGN) stock rose by 0.14% despite Truist Financial downgrading its rating from buy to hold, as several other analysts issued favorable ratings and raised price targets, contributing to overall positive sentiment around the stock.
	2024-10-14	-1.14 %
Amgen (AMGN) stock fell 1.14% following an analyst downgrade that suggested the potential financial benefits of its weight-loss drug have already been factored into the stock price. Amgen (AMGN) stock fell by 1.14% following a significant reduction in holdings by Simplicity Wealth LLC, which decreased its shares in the company by 93.0% in the third quarter. Amgen (AMGN) stock fell by 1.14% after Truist Financial downgraded it from a "buy" to a "hold" rating in their latest report. Amgen (AMGN) stock fell by -1.14% due to broader market sentiment affecting pharmaceutical stocks, driven by concerns around Pfizer's management and financial performance amid aggressive criticism and a proxy fight initiated by activist investor Starboard Value.
	2024-10-11	+2.29 %
Amgen (AMGN) stock rose by 2.29% amid mixed trading on major stock indexes, with analysts viewing it positively as the company is building a flat base that indicates potential growth, and investor sentiment remains strong amidst fluctuating market conditions influenced by recent inflation data and corporate earnings reports. Amgen (AMGN) stock rose 2.29% due to positive adjustments in hedge fund positions, favorable research ratings from analysts, and strong revenue growth reported in its recent quarterly earnings. Amgen (AMGN) stock increased by 2.29% due to institutional investors, such as Steigerwald Gordon & Koch Inc. and Vanguard Group, buying more shares, reflecting growing confidence in the company's performance and positive analyst ratings despite slightly missing earnings estimates. Amgen (AMGN) stock increased by 2.29% due to increased investments from various hedge funds and positive analyst ratings, indicating growing confidence in the company's performance and potential. Amgen (AMGN) stock rose 2.29% following GEM Asset Management LLC's increase in its stake by 14.2%, suggesting growing investor confidence and interest in the company's shares, alongside other hedge funds also raising their holdings in the stock. Amgen (AMGN) stock rose 2.29% last night, likely fueled by increased institutional investment, positive earnings performance despite a miss on EPS, and analysts' favorable ratings and price target adjustments.
	2024-10-10	-0.43 %
Amgen (AMGN) stock decreased by 0.43% following news that Alvotech's Marketing Authorization Application for a biosimilar to its drugs Prolia and Xgeva was accepted by the European Medicines Agency, indicating potential competition and reduced market exclusivity for Amgen's products. Amgen (AMGN) stock fell by 0.43% to $322.08, partly due to mixed earnings results that missed analyst expectations and concerns raised by brokerages regarding the stock's valuation, with warnings from some analysts about potential underperformance. The article primarily discusses Alvotech's acceptance of a Marketing Authorization Application by the European Medicines Agency for its biosimilar candidate AVT03, which could impact Amgen's products Prolia and Xgeva, leading to a -0.43% decrease in Amgen's stock price due to increased competition in the biosimilar market that may affect its revenue. Amgen (AMGN) stock dropped by 0.43% following the recent acquisition of shares by USA Financial Formulas, indicating ongoing market fluctuations and possibly investor reactions to hedge fund activities. The article discusses the tensions between activist investor Starboard Value and Pfizer, highlighting criticisms against CEO Albert Bourla regarding stock performance and acquisition strategies, ultimately framing them as misleading given the pharmaceutical industry's current landscape. Amgen (AMGN) stock may have declined by -0.43% due to broader market sentiments affecting pharmaceutical companies, especially in light of Pfizer's struggles, which reflect investor caution towards the sector as a whole.
	2024-10-09	+1.49 %
Amgen (AMGN) stock rose 1.49% following a report that Talbot Financial LLC increased its holdings in the company by 4.2% in the third quarter, indicating positive investor sentiment and confidence in Amgen's performance. Amgen (AMGN) stock rose 1.49% due to increased institutional investment, with several firms significantly boosting their positions in the company during the third quarter, indicating strong confidence in its future performance. Amgen (AMGN) stock rose 1.49% as several institutional investors, including Strategic Wealth Partners Ltd. and Vanguard Group Inc., increased their holdings in the company, indicating strong investor confidence and interest in Amgen's performance. Amgen (AMGN) stock rose by 1.49% following significant institutional investment increases and positive analyst ratings, indicating strong investor confidence and interest in the company's growth potential. Amgen (AMGN) stock gained 1.49% as institutional investors, including Daymark Wealth Partners LLC and others, increased their holdings, indicating confidence in the company’s prospects, alongside positive adjustments in analyst ratings and price targets.
	2024-10-08	+0.07 %
Azzad Asset Management Inc. significantly increased its stake in Amgen Inc. by 44.9% in the 3rd quarter, which may have contributed to a slight rise in Amgen's stock by 0.07%. The stock's increase could be attributed to positive investor sentiment following this notable increase in institutional ownership.
	2024-10-07	-0.69 %
Amgen (AMGN) stock fell by 0.69% despite a price target increase from Barclays, which may indicate investor concerns or market reactions unrelated to the firm's positive report. Amgen (AMGN) stock decreased by 0.69% last night, despite GAMMA Investing LLC increasing its position in the company by 25.7% in the 3rd quarter. The decline in stock value may be attributed to general market fluctuations or company-specific news, although the article does not provide explicit reasons for the drop.
	2024-10-04	+0.69 %
Amgen (AMGN) stock rose 0.69% following the purchase of 52,856 shares by the Healthcare of Ontario Pension Plan Trust Fund, indicating increased institutional interest in the company. Amgen (AMGN) stock rose by 0.69% recently as investors are optimistic about the company's ongoing development of a monthly weight-loss shot, amidst intense competition in the obesity drug market where traditional industry leaders are facing stiff challenges from emerging biotech firms like Viking Therapeutics.
	2024-10-03	-0.7 %
Amgen (AMGN) stock declined by 0.7% following the news of Sanctuary Advisors LLC acquiring a new stake in the company, which may have contributed to market volatility or investor sentiment.
	2024-10-02	-0.18 %
Amgen (AMGN) stock fell by 0.18% due to a combination of mixed financial performance, with earnings slightly missing estimates, and a decrease in price targets from several brokerages, which may have affected investor sentiment. Amgen (AMGN) stock decreased by 0.18% due to a mixed market response to recent earnings results, which saw the company miss earnings expectations despite reporting an increase in revenue.
	2024-09-30	-0.14 %
Amgen (AMGN) stock decreased by 0.14% following an announcement that Duff & Phelps Investment Management Co. significantly reduced its holdings in the company by 80.2% in the second quarter, which may have raised concerns among investors.
	2024-09-27	+1.12 %
Amgen (AMGN) stock rose by 1.12% despite Caxton Associates LP significantly reducing its stake in the company, which may indicate positive market sentiment or investor confidence in Amgen's performance. Amgen (AMGN) stock rose by 1.12% as the company is poised to compete in the rapidly expanding weight loss drug market, which is projected to grow significantly, though Eli Lilly currently leads with its successful drugs. The stock increase may reflect optimism about Amgen's potential entry and competitiveness in a lucrative market, which is expected to attract more investments and market shares as new products from competitors, including Amgen, emerge. Amgen (AMGN) stock rose 1.12% following Cantor Fitzgerald initiating coverage with an "overweight" rating and a target price of $405.00, indicating positive sentiment about the company's future performance.
	2024-09-26	+1.99 %
The article highlights the rise of Amgen (AMGN) stock by 1.99% amid a positive market trend, partly driven by the enthusiasm surrounding BioAge Labs' successful IPO and its collaboration with Eli Lilly on obesity treatments, which reflects investor optimism in the biotech sector. Amgen's stock likely increased due to favorable market trends, boosted investor confidence in biopharmaceutical collaborations, and positive developments from companies like BioAge Labs. Amgen (AMGN) stock rose by 1.99% despite Toronto Dominion Bank reducing its holdings in the company, indicating a potential positive investor sentiment or other favorable market factors contributing to the stock's increase. Amgen's stock (AMGN) rose by 1.99% following the restatement of its "outperform" rating by Royal Bank of Canada, which set a price target of $362.00 for the company. Amgen (AMGN) stock rose 1.99% as investors recognized its strong position in the rare disease market, boosted by a significant acquisition and accelerating product sales, amidst a favorable monetary environment created by the Federal Reserve's policies. Amgen (AMGN) stock rose by 1.99% amid positive sentiment in the market following Pfizer's decision to withdraw its sickle cell drug, Oxbryta, after patient deaths, leading investors to pivot towards other companies working on sickle cell treatments, which benefited from the news.
	2024-09-25	-5.46 %
Amgen (AMGN) stock declined by 5.5% due to concerns that the results from its Phase 3 clinical trial for an eczema treatment, while meeting its primary endpoint, may not be strong enough to compete effectively in a market dominated by the existing medication Dupixent, developed by rivals Sanofi and Regeneron. Amgen (AMGN) stock dropped by 5.46% following an investor update that revealed Phase 3 trial data for its drug rocatinlimab, which, while outperforming placebo for atopic dermatitis, fell short of expectations compared to competitors, prompting concerns about market competitiveness. Amgen's stock (NASDAQ:AMGN) dropped 5.46% following the reissuance of an "underperform" rating by Robert W. Baird, which also set a $215.00 price target for the company. Amgen Inc. (NASDAQ:AMGN) shares dropped 4.6% on Wednesday, trading at $315.79, amid significantly lower trading volume and possibly influenced by broader market trends or company-specific news. The decline in Amgen's stock price may be attributed to negative market sentiment or news affecting the biotech sector, which is common during periods of investor uncertainty. Amgen (AMGN) stock fell by 5.46% primarily due to fluctuations in market sentiment and investor behavior, despite a significant increase in holdings by the Public Sector Pension Investment Board.
	2024-09-24	-1.4 %
Amgen (AMGN) stock fell by 1.4% following XTX Topco Ltd's recent acquisition of 2,115 shares, which might have sparked concerns about market sentiment or overall investor confidence in the company despite the new institutional investment. Amgen (AMGN) stock fell 1.4% due to a legal setback where a federal judge ruled against Regeneron Pharmaceuticals' bid to block Amgen's entry into the market with a biosimilar version of Eylea, raising concerns about competition. Amgen (AMGN) stock fell by 1.4% after Chief District Judge Thomas Kleeh denied Regeneron Pharmaceuticals' attempt to block the sale of Amgen's Eylea biosimilar, which may have raised concerns about ongoing legal battles and the market dynamics for the drug. Amgen (AMGN) stock fell by 1.4% due to a federal judge ruling against Regeneron Pharmaceuticals in a patent dispute involving Eylea, which negatively impacted investor sentiment towards Amgen.
	2024-09-23	-0.52 %
Amgen (AMGN) stock decreased by 0.52% last night, likely due to broader market movements affecting the Dow Jones Industrial Average and changing investor sentiment towards biotechnology stocks. Amgen (AMGN) stock experienced a decline of 0.52% amid broader market gains, likely influenced by a legal setback involving a patent dispute over a competitor's drug related to its blockbuster offering, Eylea.
	2024-09-18	+0.04 %
The article explores the correlation between nasal epithelial gene expression and asthma, suggesting that profiling these genes can help identify asthma endotypes for personalized treatment. Amgen (AMGN) stock likely increased by 0.04% due to positive market sentiment or investor confidence related to advancements in asthma treatments, which may include therapeutic developments from the company.
	2024-09-17	-0.73 %
Amgen (AMGN) stock fell by 0.73% amidst an analysis indicating it is undervalued, with a fair value estimate of $580 compared to its current price of $335, primarily due to concerns over declining earnings, insufficient coverage of interest payments on debt, and slower than market-average revenue growth projections.
	2024-09-11	+0.32 %
Amgen (AMGN) stock experienced a 0.32% increase amidst a broader market decline due to new inflation data that impacted trader expectations for Federal Reserve rate cuts; the stock's resilience may be attributed to its strong fundamentals or investor confidence in its business performance relative to other stocks in the market.
	2024-09-09	+1.67 %
The Amgen (AMGN) stock rose by 1.67% due to positive developments in the treatment landscape for severe ulcerative colitis, as a systematic review outlines advancements in clinical trials and the potential for novel therapies.
	2024-09-06	-1.17 %
Amgen (AMGN) stock fell by 1.17% due to concerns over increasing competition for its key products and a potential decline in revenue as drugs like Keytruda face the loss of market exclusivity and pressure from biosimilars.
	2024-09-04	+0.04 %
Amgen (AMGN) stock was marginally up by 0.04% due to its association with Genmab's strong financial performance and developments in its product pipeline, which positively impact investor sentiment and market stability.
	2024-09-03	-0.99 %
Amgen (AMGN) stock declined by 0.99% as part of a broader market sell-off, overshadowed by the impressive vaccine results announced by Vaxcyte (PCVX), which negatively impacted the shares of established competitors like Pfizer (PFE) and Merck (MRK). Amgen (AMGN) stock declined by 0.99% following a broader market sell-off, influenced by the sharp drop in Dyne Therapeutics (DYN) stock after key executive departures and questions regarding the effectiveness of its muscular dystrophy treatment compared to existing therapies.
	2024-08-30	+0.85 %
Amgen (AMGN) stock experienced a 0.85% increase amid a market rally, as investors reacted positively to developments in the competitive cardiomyopathy drug market, particularly in light of Alnylam Pharmaceuticals' disappointing clinical trial results for its rival treatment.

1
500 / page